Trial Information

Summary: The High-Dose Aldesleukin (IL-2) Select Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Metastatic Renal Cell Carcinoma

You have been asked to participate in this research study because you have kidney cancer that has spread beyond your kidney and is not curable by surgery.  The purpose of this study is to learn more about which types of kidney cancer patients are more likely to benefit from aldesleukin (IL-2, Interleukin-2, a synthetic form of a protein that the body produces naturally that modifies the body’s response to cancer cells.) The treatment on this study is standard, not investigational.  In an attempt to identify factors that predict response to aldesleukin, the study doctors will collect subject information, blood and tumor samples prior to treatment and tumor measurements after treatment.   Your participation in this study is expected to last up to 40 weeks. When treatment is complete, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:39:31 PM